CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 50 enrolled / 50 target
Drug / intervention
Sunitinib +1 moredrug
Likely dose
Sunitinib 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00715442
NCT00715442Phase 2ActiveUpdate Overdue (0.2/mo)
CompareCT.gov

Phase II Non-Randomized Pre-Surgical Study Evaluating Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) Who Are Eligible for Cytoreductive Nephrectomy

M.D. Anderson Cancer Center·interventional·Posted Jul 15, 2008·Updated Jun 12, 2026

In Brief

A Phase 2 clinical trial evaluating Sunitinib and Nephrectomy for Renal Cell Carcinoma. Active but no longer recruiting, targeting 50 participants across 2 sites.

Signals

Enrollment appears stalled

Detailed Summary

The goal of this clinical research study is to learn if Sutent® (sunitinib malate), given before surgery, can help control renal cell carcinoma. The safety of sunitinib malate will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2Active
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 15, 2008
Enrollment StartJun 24, 2008
Primary CompletionDec 4, 2026
TodayJul 1, 2026
Enrollment to primary: 18.4 yearsPosted 18.0 years agoPrimary completion in 5 months

Arms & Interventions

Sunitinib + Nephrectomyexperimental

Sunitinib 50 mg by mouth daily for 28 consecutive days. Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.

Drug: SunitinibProcedure: Nephrectomy

Interventions

Sunitinibdrug

50 mg by mouth daily for 28 consecutive days

Nephrectomyprocedure

Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.